Table 1.
All referenced studies demonstrating CBD’s in vivo effects in brain-localized pathologies
| Article | Dosage | Model | Time/route of administration | Pathology being evaluated | CBD molecular/cellular interactions & physiologic effects |
|---|---|---|---|---|---|
| Hayakawa, 2008.52 | 0.1, 1, & 3 mg/kg | Male ddY mice | Before & 3 h after occlusion (i.p.) | Left MCA occlusion | ↓HMBG1, ↓MPO, ↓microglia activity |
| Mecha, 2013.53 | 5 mg/kg | Female SJL/J mice | 1–7 & 1–10 days post-infection (i.p.) | Demyelination | ↓VCAM, ↓TNF-α, ↓IL-1β, ↓microglia activity |
| Martín-Moreno, 2011.54 | 20 mg/kg | C56/B16 mice | Daily for 1 week and 3 × /week for the next 2 weeks after Aβ injection | Alzheimer’s disease | ↓IL-6 mRNA, ↓cognitive deficit |
| Pazos, 2013.72 | 1 mg/kg | Newborn pigs | 30 min after HI (i.v.) | Hypoxia–ischemia | ↓Glu/NAA ratio, ↓IL-1, prevented ↓GSH/creatine ratio |
| Lafuente, 2011.78 | 0.1 mg/kg | Newborn pigs | 15 & 240 min after HI (i.v.) | Hypoxia–ischemia | ↓TNF-α, ↓neuronal cell death |
| Hayakawa, 2009.81 | 3 mg/kg | Male ddY mice | Daily 1–14, 3–12, & 5–10 days after occlusion (i.p.) | Left MCA occlusion | ↓HMBG1 |
| Hayakawa, 2007.92 | 1 & 3 mg/kg | Male ddY mice | Right before, 3 & 4 h after occlusion (i.p.) | MCA occlusion | ↑CBF, ↓MPO, no effect on excitotoxicity |
| Yokubaitis, 2021.93 | 0.3, 1, 3 mg/kg | C57B/6 mice | 1 h before and 24 h after induction | Cold light ischemia | ↓infarct size, ↓microglia activity |
| Abrantes De Lacerda Almeida, 2019.121 | 1 mg, 10 mg, 10 mg/kg | Wester rats | Multiple groups; pretreatment, 1 h after induction, daily × 7 days | Germinal Matrix Hemorrhage | ↓astrocyte reactivity, ↓apoptotic cells, ↓caspase-3 |